Oncology Biomarkers Market 2024 : Industry Analysis, Trends, Segmentation, Regional Overview And Forecast 2033

Overview and Scope
Oncology biomarkers refer to the biological molecules in a patient's body that suggest the presence of cancer in the patient. Oncology biomarkers provide information about cancer in a person's body.

Sizing and Forecast
The oncology biomarkers market size has grown rapidly in recent years. It will grow from $13.68 billion in 2023 to $15.69 billion in 2024 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to adoption in emerging economies, precision medicine initiatives, diagnostic innovations, drug development support, increased cancer incidence.

The oncology biomarkers market size is expected to see rapid growth in the next few years. It will grow to $26.09 billion in 2028 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to integration of next-generation sequencing (ngs), expansion of biomarker informatics, focus on predictive pharmacogenomics, rapid development of exosome-based biomarkers, adoption of spatial transcriptomics. Major trends in the forecast period include standardization and quality assurance, shift towards functional biomarkers, role of biomarkers in clinical trials, expanded applications in immunotherapy, real-time monitoring of treatment responses.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

The oncology biomarkers market covered in this report is segmented –

1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers
2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Other Profiling Technologies
3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types
4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications
5) By End-User: Hospitals, Academic And Cancer Research Institutes, Ambulatory Surgical Centers, Diagnostic Laboratories

North America was the largest region in the oncology biomarkers market in 2023. The regions covered in the oncology biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12493&type=smp

Major Driver Impacting Market Growth
The rising incidence of cancer is expected to propel the growth of the oncology biomarker market going forward. Cancer is a disease in which some cells of the body grow uncontrollably and slowly spread to the rest of the body. Oncological biomarkers provide more information about the type of cancer by looking at the genes, proteins, and other substances in a person's body. For instance, in February 2021, according to a report published by the American Cancer Society, a US-based voluntary health organization focused on cancer, an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020. Further, in March 2023, according to the reports shared by the American Society of Clinical Oncology (ASCO)., a US-based professional organization, it was estimated that more than 12,000 people in the US were diagnosed with neuroendocrine tumors yearly. Further, approximately 171,000 people were living with this diagnosis in 2023. Therefore, the rising incidence of cancer will drive the oncology biomarker market.

Key Industry Players
Major companies operating in the oncology biomarkers market report are F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Eli Lilly and Company, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Charles River Laboratories International Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Bristol -Myers Squibb Company, Agendia Inc., Epigenomics AG, OncoDNA SA.

The oncology biomarkers market report table of contents includes:

1. Executive Summary

2. Oncology Biomarkers Market Characteristics

3. Oncology Biomarkers Market Trends And Strategies

4. Oncology Biomarkers Market - Macro Economic Scenario
..............

32. Global Oncology Biomarkers Market Competitive Benchmarking

33. Global Oncology Biomarkers Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Oncology Biomarkers Market

35. Oncology Biomarkers Market Future Outlook and Potential Analysis

36. Appendix

https://goodprnews.com/offshore-pipeline-market-insights/

https://goodprnews.com/particle-therapy-market-forecast/